Lei, Janet Jacobus, Egon J. Taverner, William K. Fisher, Kerry D. Hemmi, Silvio West, Katy Slater, Lorna Lilley, Fred Brown, Alice Champion, Brian
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundOncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytotoxicity to cancer cells with a proinflammatory cell lysis. Due to their additional potential to express immunomodulatory transgenes...
Bastin, Donald Aitken, Amelia S. Pelin, Adrian Pikor, Larissa A. Crupi, Mathieu J. F. Huh, Michael S. Bourgeois-Daigneault, Marie-Claude Bell, John C. Ilkow, Carolina S.
Published in
Journal for ImmunoTherapy of Cancer
Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the immune system and limits virus propagation. Tumour-specific defects in interferon signaling enhance viral infection and responses to oncolyt...
Hammond, Edward Haynes, Nicole M. Cullinane, Carleen Brennan, Todd V. Bampton, Darryn Handley, Paul Karoli, Tomislav Lanksheer, Fleur Lin, Liwen Yang, Yiping
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundPixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation of natural killer (NK) cells. Preclinically, pixatimod inhibits heparanase (HPSE) which may be associated with its inhibitory effec...
MacGregor, Heather L. Sayad, Azin Elia, Andrew Wang, Ben X. Katz, Sarah Rachel Shaw, Patricia A. Clarke, Blaise A. Crome, Sarah Q. Robert-Tissot, Celine Bernardini, Marcus Q.
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundB7-H3 and B7-H4 are highly expressed by many human malignancies making them attractive immunotherapeutic targets. However, their expression patterns and immune contexts in epithelial ovarian cancer have not been well characterized.MethodsWe used flow cytometry, immunohistochemistry, and genomic analyses to determine the patterns of B7-H3,...
Qualls, David Seethapathy, Harish Bates, Halla Tajmir, Shahein Heidari, Pedram Endres, Paul Reynolds, Kerry Lawrence, Donald Sise, Meghan
Published in
Journal for ImmunoTherapy of Cancer
BackgroundAcute interstitial nephritis is an immune-related adverse event that can occur in patients receiving immune checkpoint inhibitor therapy. Differentiating checkpoint inhibitor-associated acute interstitial nephritis from other causes of acute kidney injury in patients with cancer is challenging and can lead to diagnostic delays and/or unwa...
Rini, Brian I. Battle, Dena Figlin, Robert A. George, Daniel J. Hammers, Hans Hutson, Tom Jonasch, Eric Joseph, Richard W. McDermott, David F. Motzer, Robert J.
...
Published in
Journal for ImmunoTherapy of Cancer
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VE...
Berger, Alexandra Colpitts, Sarah J. Seabrook, Melanie S. S. Furlonger, Caren L. Bendix, Maura B. Moreau, Joshua M. McKillop, William M. Medin, Jeffrey A. Paige, Christopher J.
Published in
Journal for ImmunoTherapy of Cancer
Cytokines of the common γ-chain receptor family such as IL-15 are vital with respect to activating immune cells, sustaining healthy immune functions, and augmenting the anti-tumor activity of effector cells, making them ideal candidates for cancer immunotherapy. IL-15, either in its soluble form (IL-15sol) or complexed with IL-15Rα (IL-15Rc), has b...
Shah, Neil J. Al-Shbool, Ghassan Blackburn, Matthew Cook, Michael Belouali, Anas Liu, Stephen V. Madhavan, Subha He, Aiwu Ruth Atkins, Michael B. Gibney, Geoffrey T.
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundPatients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing malignancies. The safety and efficacy of ICI therapy in patients with both cancer and chronic viral infections is not well established as most clinical trials of ICIs excluded the...
Abu-Sbeih, Hamzah Herrera, Lauren Nicholas Tang, Tenglong Altan, Mehmet Chaftari, Anne-Marie Okhuysen, Pablo C. Jenq, Robert R. Wang, Yinghong
Published in
Journal for ImmunoTherapy of Cancer
Following publication of the original article [1], the authors have reported that an author’s name has been incorrectly spelled: the correct given name is Anne-Marie (instead of Anne-Maria P) and family name is Chaftari.
Massarelli, Erminia Lam, Vincent K. Parra, Edwin R. Rodriguez-Canales, Jaime Behrens, Carmen Diao, Lixia Wang, Jing Blando, Jorge Byers, Lauren A. Yanamandra, Niranjan
...
Published in
Journal for ImmunoTherapy of Cancer
IntroductionOX-40 co-stimulatory signaling plays a role in mounting anti-tumor immune responses and clinical trials targeting this pathway are ongoing. However, the association of with OX-40 protein expression with clinical outcomes and pathological features in non-small cell lung cancer (NSCLC) are largely unknown.MethodsSurgically-resected stage ...
